Over the years, patients with AMD have asked me about various unproven therapies for AMD. As is the case for many chronic, progressive diseases with limited treatments, a number of “treatments” have been proposed, tried, and/or sold for AMD. This includes electrotherapy, magnet therapy, plasmapheresis, the Outback Vision Protocol, and, worst of all, a blinding stem cell therapy. These have limited or non-existent data to support their effectiveness, but desperate patients who are losing vision will sometimes be convinced to try them.
Effective Treatments for Wet Macular Degeneration
In contrast, there are treatments proven by clinical trials for wet AMD. These include the anti-VEGF drugs bevacizumab (Avastin®), ranibizumab (Lucentis®), aflibercept (Eylea®), and brolucizumab (Beovu®). Please discuss the benefits and risks of each option with your doctor.
Effective Treatments for Dry Macular Degeneration
How to Tell if a Clinical Trial is a Scam
There are also drugs in clinical trials. Patients who meet enrollment criteria can enroll in these. But how do you tell the difference between a bona fide clinical trial and a scam? One way is price. Typically, real clinical trials will be paid for by a pharmaceutical company that wants to test its drug, or by a grant from the NIH or an eye research foundation. So, patients should expect not to be asked to pay anything beyond what they usually pay for the routine standard of care, or sometimes nothing at all. Profiteering clinics with unproven and, sometimes, unsafe treatments will likely charge thousands of dollars.
This was the recent case with a private clinic offering stem cell therapy for AMD. The company extracted cells from belly fat and injected them into the eyes of three patients with AMD. The patients had horrible complications as these inappropriate cells divided and caused inflammation, resulting in severe loss of vision. Even worse, both eyes were injected, so both eyes suffered this fate. Bona fide ocular clinical trials would rarely, if ever, treat both eyes. Treating only one eye ensures that the other eye will not be affected if there’s an adverse event or side effect.
Clinical trials should be reviewed prior to initiation by an independent institutional review board (IRB), and monitored by a data safety and monitoring board (DSMB). They may be conducted at university hospitals and/or private doctors’ offices.
For patients, navigating to proven, safe treatments, or well-run clinical trials can be confusing, especially in this era of unfiltered and often inaccurate information flooding the Internet.
The Best Advice
The bottom line is that the best way to find an appropriate treatment is to follow the advice of a well-qualified, trusted doctor. If you have any doubts about the doctor’s recommendations, get a second opinion from a doctor in a different practice group or institution. Stay away from the snake oil!
- Macular Degeneration Toolkit (Helpful Information to Understand and Manage Macular Degeneration)
- Expert Information on Macular Degeneration (Articles)
- BrightFocus Chats (Audio Presentations on Macular Degeneration)
- Treatments for Age-Related Macular Degeneration (Fact Sheet)
- Clinical Trials: Your Questions Answered (Publication)
This content was last updated on: May 6, 2020
The information provided here is a public service of the BrightFocus Foundation and should not in any way substitute for personalized advice of a qualified healthcare professional; it is not intended to constitute medical advice. Please consult your physician for personalized medical advice. BrightFocus Foundation does not endorse any medical product, therapy, or resources mentioned or listed in this article. All medications and supplements should only be taken under medical supervision. Also, although we make every effort to keep the medical information on our website updated, we cannot guarantee that the posted information reflects the most up-to-date research.
These articles do not imply an endorsement of BrightFocus by the author or their institution, nor do they imply an endorsement of the institution or author by BrightFocus.
Some of the content may be adapted from other sources, which will be clearly identified within the article.